Abbreviations: MAC = myeloablative conditioning; PMN = polymorphonuclear neutrophils; Plt = platelets; RIC = reduced-intensity conditioning.
Allogeneic stem cell transplantation (ASCT) remains a major therapeutic modality in many high-risk hematological diseases. [1] [2] [3] [4] [5] With the improvement of conditioning chemotherapy and supportive care, the outcome of this strategy has improved. 6 Yet a major issue remains, which is the quest for a fully-matched donor. Current strategies usually consist in selecting a matched related donor and, if not available, a matched unrelated donor. When this is not fruitful, choices move down to partially-matched (9/10e) unrelated donors or umbilical cord blood units. 7 Although this strategy is likely to identify a graft, for some patients, finding a suitable donor is not possible. For the past few years, ASCT using family donors with only one identical HLA haplotype, also known as haploidentical ASCT (H-ASCT) [8] [9] [10] [11] [12] [13] has helped to circumvent this hindrance, allowing us to propose ASCT to most patients. Yet this strategy involves increased toxicities such as GvHD and higher graft failure. [14] [15] This led to highly immunosuppressive conditioning and immediate post-transplant strategies based partly on the use of post-transplantation cyclophosphamide (PTCY). 11, 14 Little is known about the impact of this aggressive strategy in terms of hematological recovery, transfusion needs and infection risks. Here, we report early hematological recovery in a paired cohort of 44 patients, half of them having received H-ASCT.
This single-center study performed between May 2011 and June 2015 enrolled 22 patients with T-replete H-ASCT and 22 matched patients with a non-haploidentical ASCT (NH-ASCT) grafted during the same period. Patients were paired by age (51.2 years old in the H-ASCT group versus 50.9 years old in the NH-ASCT group, P = NS) and initial disease (6 acute myeloid leukemias, 9 acute lymphoblastic leukemias, 3 myelodysplastic syndromes, 3 non-Hodgkin's lymphomas and 1 myelofibrosis in each group). Both groups were also similar in terms of gender (50% versus 73% males, P = NS), previous transplantation (36% versus 9%, P = NS), disease status at transplantation (complete response: 73% versus 68%, P = NS), dose of CD34+ cells infused (7.7 ± 0.7 × 10 6 versus 6.3 ± 0.6 × 10 6 /kg, P = NS). All grafts were of PBSC (Table 1 ). In the H-ASCT group, all patients but three received a reduced-intensity conditioning (RIC). The latter three received a sequential regimen. All H-ASCT patients received 50 mg/kg of cyclophosphamide on days 3 and 4 post transplant. Three patients received G-CSF post transplant until hematological recovery. Three patients also received EPO (n = 2) and/or TPO (n = 2). In the NH-ASCT group, 6 patients received a myeloablative conditioning, 14 a RIC and 2 a sequential conditioning regimen. Clofarabine-containing RIC was administered in respectively 32% of the H-ASCT and 14% of the NH-ASCT patients (P = NS). In this subgroup, two patients also received G-CSF until hematological recovery, but none were given EPO nor TPO. In the NH-ASCT group, there were 12 familial and 10 matched unrelated donors. Donors and recipients were gender-matched in 55% of H-ASCT and in 87% of NH-ASCT ( Table 1) .
The primary end points were to evaluate, during the 60 days following ASCT, the delay in recovery of polymorphonuclear neutrophils (PMNs), RBC and platelets (Plt). Recovery was defined respectively as the first of three consecutive days with a PMN40.5 × 10 9 /L, a stabilized level of hemoglobin 48 g/dL, 415 days without RBC infusion and platelets steadily over 20 × 10 9 /L without platelet infusion. The secondary end points were the numbers of RBC and Plt infusions, early engraftment status measured by whole blood chimerism at day +30 post ASCT, viral reactivations of CMV and/or EBV and incidence of relapse during the 60 days follow-up. Chimerism was evaluated at day +30 post ASCT in whole blood. Chimerism assessment was based on molecular biology in patients with a sex-matched donor and on FISH in patients with a matched donor of a different gender.
Variables were tested for normality using a KolmogorovSmirnov test. They were compared using a Fisher exact test for qualitative variables and the Mann-Whitney test for quantitative variables. Variables were considered significantly different for a P-value o 0.05.
With a follow-up of 60 days after ASCT, median times to PMN recovery were similar in both H-ASCT and in NH-ASCT patients, respectively at 18 days (95% CI 17-22) and 18.5 days (95% CI 17-20, P = NS). Conversely, the median time to RBC and Plt recovery was significantly different between the H-ASCT and the NH-ASCT groups. The median time to RBC recovery was 22 days (95% CI 15-32) for H-ASCT patients versus 10 days (95% CI 4-18, P = 0.0018) for NH-ASCT patients and the median time to Plt recovery was 26.5 days (95% CI 18-51.5) versus 10.5 days (95% CI 9-13, P = 0.004), respectively. Pointing toward the same direction, the numbers of infused RBC and Plt units were increased in the H-ASCT group, at respectively 7 units (95% CI 4-8) versus 2 (95% CI 2-4, P = 0.0014) and 11 units (95% CI 7-21) versus 3 (95% CI 2-10, P = 0.005).
Interestingly, this difference in terms of blood count recovery did not reveal any delay of engraftment, as chimerism at day +30 was 99% (95% CI 99.4-99.9) for H-ASCT and 98% for NH-ASCT (95% CI 92.5-99.3, P = 0.01).
The incidence of CMV reactivation was similar in both the groups, but there were significantly more early EBV reactivations in the group of NH-ASCT patients (12 versus 5, P = 0.01). H-ASCT also did not result in an increased number of early viral reactivations, nor did any relapse occur (1 versus 2, P = NS). Four patients in the H-ASCT group suffered from hemorrhagic cystitis associated with BK virus infection, but only one before hematological recovery. One patient in the NH-ASCT group suffered from digestive hemorrhage.
Although this series of paired patients is relatively small, it allows clear demonstration that the hematological recovery was significantly different between paired H-ASCT versus NH-ASCT patients, especially for RBC and platelet transfusion requirements. The rate of platelet recovery was shorter than in the study of Wang et al., 13 yet longer than in NH-ASCT as reported by these authors. However, we also found a significant difference for RBC reconstitution, a feature seldom explored in the literature.
This difference might be partially explained by the direct cytotoxicity of PTCY. However, six patients with NH-ASCT received post-transplantation methotrexate with no impact on recovery. Moreover, the use of PTCY had no impact in terms of PMNs recovery, underlying the fact that specific mechanisms are implied by the difference of hematological recovery in the various lineages, as well as between H-ASCT and NH-ASCT receivers.
14 Of note, as respectively only three and two patients received G-CSF in the two groups, this is unlikely to have made any difference in the recovery delay. The drugs used in the conditioning were also similar in both the groups with the exception of PTCY, excluding a potential impact of prior transplantation chemotherapy on hematological recovery. Underlying the disease, disease status at ASCT and prior transplantation can also be ruled out as explanations for these differences, as there were no statistical differences in these three parameters between the two groups examined. According to the current recommendations, 12 although not statistically significant, H-ASCT had a higher number of CD34+ cells infused, but it is unlikely that this difference might explain the observed differences reported here.
Immunological conflicts between grafted and donor cells might also play a role in the hematological recovery delay in H-ASCT, but this was not explored in this study. It is possible that by reducing the efficiency of alloreactive T cells in vivo, the use of a highly immunosuppressive strategy, including PTCY, may increase the time to engraftment after ASCT although the engraftment at day +30 was higher in the H-ASCT group. 14 Another explanation for the longer delay in platelet and red blood cell recovery lies in the possible difference in the disease control between the two groups. However, no difference was pointed out in terms of early progression free survival.
Although these data require confirmation in a larger prospective cohort, this study underlines that a longer delay in RBC and platelet recovery is demonstrated for H-ASCT patients, at least partially explained by the PTCY therapy accompanying this procedure. Whether other mechanisms play a role in post-haplo-ASCT recovery is not clear. It might be interesting to study the impact of the disease status and immunological recovery early after transplantation in order to fully understand the nature of this delay.
